Regeneron Pharmaceuticals' Income towards Parent Company fell 796.56% to $844.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 209.17%. This contributed to the annual value of $4.5 billion for FY2025, which is 209.17% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Income towards Parent Company stood at $844.6 million for Q4 2025, which was down 796.56% from $1.5 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Income towards Parent Company ranged from a high of $3.1 billion in Q2 2021 and a low of $722.0 million during Q1 2024
Its 5-year average for Income towards Parent Company is $1.3 billion, with a median of $1.1 billion in 2021.
In the last 5 years, Regeneron Pharmaceuticals' Income towards Parent Company skyrocketed by 24535.83% in 2021 and then crashed by 7250.31% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Income towards Parent Company stood at $2.2 billion in 2021, then plummeted by 46.29% to $1.2 billion in 2022, then dropped by 3.13% to $1.2 billion in 2023, then dropped by 20.86% to $917.7 million in 2024, then dropped by 7.97% to $844.6 million in 2025.
Its last three reported values are $844.6 million in Q4 2025, $1.5 billion for Q3 2025, and $1.4 billion during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value